A landmark European stem cell trial for Parkinson’s disease has reported encouraging first results. In the STEM-PD trial, led by Lund University in Sweden and the University of Cambridge in the UK, 6 of 7 participants were able to reduce their Parkinson’s medication about a year after surgery, Parkinson’s UK reported on July 9, 2026.
What the trial found
- Cells took hold: Brain scans of all 7 participants showed the transplanted cells had settled well in the target area of the brain.
- No unexpected side effects: The surgery caused no unexpected side effects.
- Fewer symptoms: Six of the seven participants reduced their dopamine medication and reported fewer Parkinson’s symptoms.
Parkinson’s UK called the results an exciting development and a milestone built on decades of research. The charity noted that the medication reductions were especially encouraging.
Why this trial is different
STEM-PD is a carefully controlled clinical trial. The cells are made in a regulated laboratory to replace the dopamine-producing brain cells that Parkinson’s destroys, and they are placed precisely by surgery. Participants are followed closely and the results are reported openly. The trial is still small and early, and larger studies will be needed to confirm the benefits.
What it means for regenerative medicine patients
Patients often see stem cell treatments advertised for many conditions, including in Tijuana. Results like STEM-PD’s come from trials with defined cell products, safety monitoring and published outcomes. When you evaluate any clinic, ask:
- Is this treatment part of a registered clinical trial?
- What exactly are the cells, and how are they made and tested?
- Is the clinic authorized by COFEPRIS for cell therapy?
- What published results support this treatment for my condition?
Resumen en español
El ensayo europeo STEM-PD, dirigido por la Universidad de Lund y la Universidad de Cambridge, reportó resultados iniciales positivos: 6 de 7 participantes con Parkinson redujeron su medicamento un año después del trasplante de células madre, y las células se implantaron bien sin efectos secundarios inesperados. Aunque el estudio es pequeño, muestra el valor de los ensayos clínicos controlados. Antes de cualquier tratamiento con células madre, se recomienda verificar la autorización de COFEPRIS y la evidencia publicada.
Source: “Landmark European stem cell trial announces positive results,” Parkinson’s UK, July 9, 2026.
This article is for general information and is not medical advice.
